John F. Seymour, MBBS, FRACP, PhD

Panelists comment on the increasing preference for fixed-duration therapy over treatment until progression, as reflected in recent guideline updates.

Panelists discuss the role of non-covalent BTKis in this setting and available supporting data (high level).

Panelists comment on the role of combination venetoclax-ibrutinib in this setting and available supporting data.

Panelists review recent ESMO guideline updates for managing early relapse after venetoclax-based time-limited therapy, managing relapse after chemoimmunotherapy or late relapse after venetoclax-based time-limited therapy and defining early versus late relapse.

Panelists discuss the ongoing trials evaluating other BCL2i/BTKi combination approaches.

Panelists review recent ESMO guideline updates for the frontline management of patients with CLL and a TP53 or del(17p) mutation.

Panelists discuss the role of ven-ibr in patient populations.

Panelists discuss the addition of doublet venetoclax-ibrutinib as a treatment option in ESMO guideline updates.

Panelists discuss, which patients are favored for the Venetoclax-Obinutuzumab treatment approach.

Panelists discuss, role of time-limited therapy with venetoclax-obi in this setting, highlighting the underlying rationale and data supporting this approach.

A panel of medical experts provides an overview of recent ESMO guideline updates on frontline management for patients with IGHV-mutated or unmutated chronic lymphocytic leukemia (CLL) without TP53 mutations, highlighting key clinical implications.

A panel of medical experts continues their discussion surrounding an array of treatment options for CLL.

Dr Niemann provides an overview of the evolving treatment landscape of CLL.

John Seymour, MBBS, FRACP, PhD, discusses the role of genetic profiling in the treatment of chronic lymphocytic leukemia.

John Seymour, MBBS, FRACP, PhD, discusses the characteristics of patient subgroups with chronic lymphocytic leukemia who may benefit from curative treatment with fludarabine, cyclophosphamide, and rituximab.

John Seymour, MBBS, FRACP, PhD, discusses the importance of targeted therapy in patients with chronic lymphocytic leukemia.

John Seymour, MBBS, FRACP, PhD, discusses the curative potential of fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia.

John F. Seymour, discusses the findings from a post-hoc analysis of the phase 3 ELEVATE-RR trial examining the adverse effects experienced with the BTK inhibitors acalabrutinib and ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia.

John F. Seymour, MBBS, FRACP, PhD, from the Department of Hematology at the Peter MacCallum Cancer Centre in East Melbourne, Australia, discusses the results of the PRIMA study, which evaluated the benefit of maintenance therapy with rituximab after induction of response with chemotherapy plus rituximab in comparison with no maintenance therapy in patients with advanced follicular lymphoma.

John F. Seymour, MBBS, FRACP, PhD, discusses the efficacy of single-agent ABT-199 (GDC-0199), a novel Bcl-2 inhibitor, in high-risk relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.